Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Array CGH analysis in gastric gastrointestinal stromal tumors (GISTs)

ABSTRACT: To explore mechanisms underlying wild-type GISTs, array CGH was performed on 32 gastric GISTs (4 risk groups stratified by tumor size and mitotic counts comprised 8 cases each).

ORGANISM(S): Homo sapiens

PROVIDER: GSE47912 | GEO | 2013/06/14

SECONDARY ACCESSION(S): PRJNA208311

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Array CGH analysis in gastric gastrointestinal stromal tumors (GISTs)

Project description:To explore mechanisms underlying wild-type GISTs, array CGH was performed on 32 gastric GISTs (4 risk groups stratified by tumor size and mitotic counts comprised 8 cases each). 27 KIT-mutant, 1 PDGFRA-mutant and 4 wild-type GISTs

2013-06-14 | E-GEOD-47912 | biostudies-arrayexpress

Gene expression signatures in gastric gastrointestinal stromal tumors (GISTs)

Project description:To explore mechanisms underlying wild-type GISTs, gene expression analysis was performed on 15 gastric GISTs.

2013-06-14 | GSE47911 | GEO

miRNA expression signatures in gastrointestinal stromal tumors (GISTs)

2011-11-01 | GSE31741 | GEO

Gene expression signatures in gastric gastrointestinal stromal tumors (GISTs)

Project description:To explore mechanisms underlying wild-type GISTs, gene expression analysis was performed on 15 gastric GISTs. 11 KIT-mutant, 1 PDGFRA-mutant and 3 wild-type GISTs

2013-06-14 | E-GEOD-47911 | biostudies-arrayexpress

Array CGH analysis of human gastrointestinal stromal tumors

Project description:Gastrointestinal stromal tumors (GISTs) are the most important mesenchymal tumors of the gastrointestinal tract. The vast majority of GISTs exhibit activating mutations of KIT or PDGFRA, but epigenetic alteration of GISTs is largely unknown. In this study, we aimed to clarify the involvement of DNA methylation in GIST malignancy. A total of 25 GIST specimens were studied using Human Genome CGH Microarray Kit 105A (G4412A, Agilent). Levels of LINE-1 methylation were analyzed using bisulfite-pyrosequencing. LINE-1 hypomethylation was correlated with risk grade, and high-risk GISTs exhibited lower levels of LINE-1 methylation than low- or intermediate-risk GISTs. Array CGH analysis revealed a significant correlation between LINE-1 hypomethylation and chromosomal aberrations. Our data suggest that LINE-1 hypomethylation correlates with the aggressiveness of GISTs. Hypomethylation may increase the malignant potential of GISTs by inducing accumulation of chromosomal aberrations.

2010-06-20 | GSE22185 | GEO

miRNA expression signatures in gastrointestinal stromal tumors (GISTs)

Project description:To clarify the microRNA (miRNA) expression signatures in gastrointestinal stromal tumors (GISTs), a series of 32 GIST specimens were analyzed using Agilent miRNA microarray V3. Unsupervised hierarchical clustering revealed that GISTs can be categorized into 2 groups according to the expression of a miRNA cluster encoded on chromosome 14q32.31. Total RNA was extracted from 32 fresh frozen GIST specimens obtained from surgical resections. Expression of 851 miRNAs was analyzed using Human miRNA Microarray V3 (Rel 12.0 G4470C; Agilent technologies, Santa Clara, CA, USA). Risk grade was assessed according to the risk definition system proposed by Fletcher et al. (Hum Pathol. 2002;33:459-65.)

2011-11-01 | E-GEOD-31741 | biostudies-arrayexpress

Array CGH analysis of human gastrointestinal stromal tumors

2010-06-20 | E-GEOD-22185 | biostudies-arrayexpress

Gene expression signatures in gastrointestinal stromal tumors (GISTs)

Project description:To analyze the gene expression signatures in gastrointestinal stromal tumors (GISTs), a series of 14 GIST specimens were analyzed using Agilent Whole Human Genome Microarray (4x44K, G4112F). Total RNA was extracted from 32 fresh frozen GIST specimens obtained from surgical resections. Gene expression was analyzed using Agilent Whole Human Genome Microarray (4x44K, G4112F, Agilent technologies, Santa Clara, CA, USA). Risk grade was assessed according to the risk definition system proposed by Fletcher et al. (Hum Pathol. 2002;33:459-65.)

2011-11-01 | E-GEOD-31802 | biostudies-arrayexpress

Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations

Project description:Abstract: Most GISTs require oncogenic activation of the KIT or PDGFRA receptor tyrosine kinase proteins, and the genomic mechanisms of oncogene activation are heterogeneous. Notably, the kinase mutation type correlates with both tumor biology and imatinib response. For example, GISTs with KIT exon 11 mutations are typically gastric and have excellent imatinib response, whereas those with KIT exon 9 mutations generally arise in the small bowel and are less responsive to imatinib. To identify genes that might contribute to these biological differences, we carried out gene expression profiling of 26 GISTs with known KIT and PDGFRA mutational status. Expression differences were then evaluated further by RNA in situ hybridization, immunohistochemistry, and immunoblotting. Unsupervised hierarchical clustering grouped tumors with similar mutations together, but the distinction between the different groups was not absolute. Differentially expressed genes included ezrin, p70S6K, and PKCs, which are known to have key roles in KIT or PDGFRA signaling, and which might therefore contribute to the distinctive clinicopathological features in GISTs with different mutation types. These gene products could serve as highly selective therapeutic targets in GISTs containing the KIT or PDGFRA mutational types with which they are associated. A disease state experiment design type is where the state of some disease such as infection, pathology, syndrome, etc is studied. Keywords: disease_state_design

2006-01-10 | GSE4001 | GEO

Gene expression signatures in gastrointestinal stromal tumors (GISTs)

2011-11-01 | GSE31802 | GEO